Table 2.
Neoadjuvant treatment regimen and outcomes by age categories
| Patients < 75 years (N = 1249) | Patients ≥ 75 years (N = 275) | P-value* | |||
|---|---|---|---|---|---|
| age < 70 (N = 916) | 70–74 (N = 333) | Age 75–79 (N = 237) | ≥ 80 (N = 38) | ||
| Interval between diagnosis and onset of neoadjuvant therapy (days), median (IQR) | 38 (29–50) | 40 (31–52) | 42 (32–54) | 44 (33–55) | < 0.001 |
| Type of neoadjuvant therapy, no./total no. (%) | 0.175 | ||||
| Chemotherapy | 899 (98.1) | 331 (99.4) | 231 (97.5) | 37 (97.4) | |
| Chemo- and targeted therapy | 17 (1.9) | 2 (0.6) | 6 (2.5) | 1 (2.6) | |
| Neoadjuvant chemotherapy regime, no./total no. (%) | < 0.001 | ||||
| EOX/ECC/EOF/ECF | 548 (59.8) | 178 (53.5) | 108 (45.6) | 11 (28.9) | |
| FOLFOX/CAPOX | 42 (4.6) | 34 (10.2) | 45 (19.0) | 9 (23.7) | |
| FLOT | 263 (28.7) | 106 (31.8) | 65 (27.4) | 12 (31.6) | |
| DOC | 18 (2.0) | 7 (2.1) | 7 (3.0) | 0 (0.0) | |
| Other | 45 (4.9) | 8 (2.4) | 12 (5.1) | 6 (15.8) | |
| Course of neoadjuvant regime no./total no. (%) | < 0.001 | ||||
| Completed all cycles | 708 (77.3) | 213 (64.0) | 148 (62.4) | 26 (68.4) | |
| Reduction in cycles | 131 (14.3) | 100 (30.0) | 71 (30.0) | 5 (13.2) | |
| Unknown | 77 (8.4) | 20 (6.0) | 18 (7.6) | 7 (18.4) | |
| Not proceeded to surgery after neoadjuvant therapy no./total no. (%) | 77 (8.4) | 34 (10.2) | 33 (13.9) | 10 (26.3) | < 0.001 |
| N = 77 | N = 34 | N = 33 | N = 10 | ||
|---|---|---|---|---|---|
| Reasons for not proceeding to surgery no./total no. (%) | 0.011 | ||||
| Non-curable disease after restaging | 23 (29.9) | 7 (20.6) | 4 (12.1) | 1 (10.0) | |
| Poor functional status | 6 (7.8) | 2 (5.9) | 10 (30.3) | 1 (10.0) | |
| Patient’s request | 4 (5.2) | 2 (5.9) | 2 (6.1) | 0 (0.0) | |
| Low tumorload | 1 (1.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Deceased | 2 (2.6) | 2 (5.9) | 1 (3.0) | 0 (0.0) | |
| Unknown | 41 (53.2) | 21 (61.8) | 16 (48.5) | 8 (80.0) |
IQR interquartile range, EOX epirubicine, oxaliplatin, capecitabine, ECC epirubicine, cisplatin, capecitabine, EOF epirubicine, oxaliplatin, 5-fluorouracil, ECF epirubicine, cisplatin, 5-fluorouracil, FOLFOX 5-fluorouracil, oxaliplatin, CAPOX capecitabine, oxaliplatin, FLOT 5-fluorouracil, leucovorin, oxaliplatin, docetaxel, DOC docetaxel, oxaliplatin, capecitabine
*P-value is based on analysis of patients < 75 years (n = 1249) versus patients ≥ 75 years (n = 275)